Details of the Drug

General Information of Drug (ID: DM2MYNQ)

• Drug Name: Piclidenoson
• Synonyms: IB-MECA; 152918-18-8; piclidenoson; CF-101; 3-IB-Meca; N(6)-Ibamu; CF 101; Cf101; UNII-30679UMI0N; CHEMBL119709; CHEBI:73286; 30679UMI0N; RPR-113090; IB-Meca

Indication

Disease Entry	ICD 11	Status	REF
Keratoconjunctivitis sicca	9A79	Phase 3	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[2]

• Drug Type: Small molecular drug
• Chemical Identifiers:
  Formula: C18H19IN6O4
  Canonical SMILES: CNC(=O)C1C(C(C(O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O
  InChI: InChI=1S/C18H19IN6O4/c1-20-17(28)14-12(26)13(27)18(29-14)25-8-24-11-15(22-7-23-16(11)25)21-6-9-3-2-4-10(19)5-9/h2-5,7-8,12-14,18,26-27H,6H2,1H3,(H,20,28)(H,21,22,23)/t12-,13+,14-,18+/m0/s1
  InChIKey: HUJXGQILHAUCCV-MOROJQBDSA-N
• Cross-matching ID:
  PubChem CID: 123683
  ChEBI ID: CHEMBL119709
  CAS Number: 152918-18-8
  UNII: 30679UMI0N
  DrugBank ID: DB05511
  TTD ID: D05SBR
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug
• Drug Pharmacogenomic Perturbation (DPP)NEW: Click to Jump to the Detailed DPP Information of This Drug
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

References

• [1] ClinicalTrials.gov (NCT01235234) Trial of CF101 to Treat Patients With Dry Eye Disease. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04333472) Piclidenoson for Treatment of COVID-19. U.S. National Institutes of Health.